Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Potentially Associated with Chemotherapy-induced Anemia in Patients with Solid Cancers

  • Cheng, Ke (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Zhao, Feng (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Gao, Feng (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Dong, Hang (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Men, Hai-Tao (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Chen, Ye (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Li, Long-Hao (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Ge, Jun (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Tang, Jie (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Ding, Jing (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Chen, Xin (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Du, Yang (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Luo, Wu-Xia (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Liu, Ji-Yan (Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Chemotherapy-induced anemia (CIA) is one of the most important causes of anemia in cancer patients. This study was conducted to describe the prevalence and characteristics of CIA in solid cancer patients in the Chinese population, and to explore the relationship of white blood cell (WBC) or platelet decrease with CIA. Methods: Data on age, gender, tumor diagnosis, anti-cancer treatment and blood cell analyses were available from 220 untreated non-anemic cancer patients who received at least 2 cycles of chemotherapy, and the data were analyzed to assess their relationship with CIA or its severity. Results: 139 patients (63.2%) presented anemia, most being Grade 1 or 2. Esophageal and lung cancers were associated with a high prevalence. G3/4 leucopenia and decrease of platelets were identified as independent risk factors for the occurrence of CIA. Moreover, G3/4 leucopenia, decrease of platelet and G3/4 thrombocytopenia were found to be also associated with the severity of CIA. Cisplatin-containing regimens were a main potential factor in causing CIA, although significant association was only found on univariate analysis. Conclusion: Anemia or decrease in hematoglobin are common in Chinese cancer patients receiving chemotherapy. Cisplatin-containing regimens might be an important factor influencing the occurrence of CIA. Our analysis firstly described some risk factors, such as decrease of platelets or WBCs, severity of leucopenia or thrombocytopenia, associated with the occurrence and severity of CIA.

Keywords

References

  1. Aapro M, Jelkmann W, Constantinescu SN, Leyland- Jones B (2012). Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer, 106, 1249-58. https://doi.org/10.1038/bjc.2012.42
  2. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012). Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol, 23, 1954-62. https://doi.org/10.1093/annonc/mds112
  3. Abdel-Razeq HN (2004). Cancer-related anemia. Saudi Med J, 25, 15-20.
  4. Achariyapota V, Benjapibal M, Chaopotong P (2010). Prevalence and incidence of anemia in Thai patients with gynecologic cancer. Asian Pac J Cancer Prev, 11, 1229-33.
  5. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E (2000). Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer, 82, 93-7. https://doi.org/10.1054/bjoc.1999.0883
  6. Barrett-Lee PJ, Ludwig H, Birgegard G, et al (2006). Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology, 70, 34-48. https://doi.org/10.1159/000091675
  7. Bohanes P, Yang D, Chhibar RS, et al (2012). Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol, 30, 2265-72. https://doi.org/10.1200/JCO.2011.38.8751
  8. Caro JJ, Salas M, Ward A, Goss G (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 2214-21. https://doi.org/10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
  9. Gao F, Cheng K, Zhao F, et al (2011). Prevalence and characteristics of anemia in patients with solid cancers at diagnosis in southwest China. Asian Pac J Cancer Prev, 12, 2825-8.
  10. Groopman JE, Itri LM (1999). Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 91, 1616-34. https://doi.org/10.1093/jnci/91.19.1616
  11. Hassan BA, Yusoff ZB (2011). Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. Asian Pac J Cancer Prev, 12, 1573-6.
  12. Hassan BA, Yusoff ZB, Hassali MA, Othman SB (2011). Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients. Asian Pac J Cancer Prev, 12, 2753-8.
  13. Knight K, Wade S, Balducci L (2004). Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med, 116, S11-26.
  14. Kosmidis P, Krzakowski M (2005). Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer, 50, 401-12. https://doi.org/10.1016/j.lungcan.2005.08.004
  15. Ludwig H, Van Belle S, Barrett-Lee P, et al (2004). The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40, 2293-306. https://doi.org/10.1016/j.ejca.2004.06.019
  16. Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000). Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev, 26, 303-11. https://doi.org/10.1053/ctrv.2000.0181
  17. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990). Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med, 322, 1689-92. https://doi.org/10.1056/NEJM199006143222401
  18. Owonikoko TK, Ragin CC, Belani CP, et al (2007). Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol, 25, 5570-7. https://doi.org/10.1200/JCO.2007.12.5435
  19. Pongsanon K, Benjapibal M, Ruengkhachorn I (2011). Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinumbased chemotherapy. Asian Pac J Cancer Prev, 12, 131-6.
  20. Rothmann SA, Weick JK (1981). Cisplatin toxicity for erythroid precursors. N Engl J Med, 304, 360.
  21. Spivak JL, Gascon P, Ludwig H (2009). Anemia management in oncology and hematology. Oncologist, 14, 43-56. https://doi.org/10.1634/theoncologist.2009-S1-43
  22. Steensma DP (2008). Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol, 26, 1022-4. https://doi.org/10.1200/JCO.2007.15.3874
  23. Tchekmedyian NS (2002). Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park), 16, 17-24.
  24. Weiss G, Goodnough LT (2005). Anemia of chronic disease. N Engl J Med, 352, 1011-23. https://doi.org/10.1056/NEJMra041809
  25. Wilairat W, Benjapibal M (2012). Presence of anemia and poor prognostic factors in patients with endometrial carcinoma. Asian Pac J Cancer Prev, 13, 3187-90. https://doi.org/10.7314/APJCP.2012.13.7.3187

Cited by

  1. Endostar Combined with Cisplatin Inhibits Tumor Growth and Lymphatic Metastasis of Lewis Lung Carcinoma Xenografts in Mice vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3079
  2. Hematologic Toxicity in Patients Undergoing Radical Anti-cancer Therapy: A Cross-Sectional Analysis of Patients in an Oncology Ward in India vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3587
  3. Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study vol.5, pp.5, 2014, https://doi.org/10.1111/1759-7714.12102
  4. Iron deficiency anemia in gastric cancer vol.30, pp.12, 2018, https://doi.org/10.1097/MEG.0000000000001251